InnoSer’s FTD mouse models portfolio is designed to capture the two major proteinopathy axes relevant to human disease: 

• Tau-associated FTD pathology: Our tau-focused model portfolio includes transgenic tau mouse models and seeding and spread tau mouse models that recapitulate key aspects of tau-driven neurodegeneration, including aggregation, spread, and progressive neuronal dysfunction. Transgenic tau models express the FTD-linked MAPT mutations such as P301S (Tau[P301S0 mouse model) and P301L (Tau[P301L] mouse model). For tau seed and spread studies, whilst we most commonly use brain extracts from aged Tau[P301S] mice, these models offer more flexibility in the choice of seeds to induce progressive propagation of tau pathology across brain regions whereby seeding studies can be performed with brain extracts obtained from patients with confirmed FTD pathology.  

• TDP-43-associated FTD pathology: InnoSer has characterized a transgenic mouse model harbouring the human ALS/ FTD-associated TDP-43 mutation (Q311K) in the TARDBP gene. The TDP-43Q311K mouse model reproduces the pathophysiological phenotypes of human ALS/FTD, namely motor dysfunction in the absence of overt TDP-43 aggregations, allowing you to perform longitudinal motor function assessment studies focusing on rescuing functional aspects of ALS and FTD.  

Reach out to our team to discuss which mouse model of FTD is the most appropriate for your next preclinical efficacy study.